Sera Prognostics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; it does not provide standalone fourth-quarter results. Sera is a women’s health diagnostics company whose commercial product, PreTRM, is a blood-based test intended to predict spontaneous preterm-birth risk in singleton pregnancies.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $82,000 | $25,000 |
| Cost of revenue | $37,000 | $11,000 |
| Operating expenses | $35.5 million | $18.0 million |
| Loss from operations | $(35.4) million | $(18.0) million |
| Net loss | $(35.0) million | $(19.8) million |
| Cash used in operating activities | $(31.6) million | $(16.9) million |
Revenue remained immaterial relative to expenses; the filing says there was no significant commercial revenue. Gross profit was approximately $45,000, but the low sales base makes margin comparisons uninformative. Research and development expense rose 42% to $11.0 million, selling and marketing rose 183% to $10.3 million, and general and administrative expense rose 115% to $14.1 million. Management attributes increases chiefly to clinical and laboratory activity, commercial hiring and launch costs, and public-company expenses.
At year-end, cash and cash equivalents were $58.9 million and available-for-sale securities were $81.0 million, totaling about $140.0 million. Total assets were $147.0 million; total liabilities were $8.5 million. Sera reported no outstanding debt, though it had approximately $0.1 million of capital-lease obligations. Management said existing resources were expected to fund operations and capital requirements for at least 12 months from the financial-statement issuance date. The company remained loss-making, with an accumulated deficit of $166.5 million.
Material changes and notable items
- Net loss increased by $15.2 million year over year, while operating cash use increased by $14.8 million.
- Sera completed its July 2021 IPO, receiving $66.6 million in net proceeds, and raised approximately $100.1 million net from Series E preferred stock. Preferred stock converted to common stock in connection with the IPO; year-end stockholders’ equity was $138.6 million.
- All outstanding debt was repaid during 2021. A $1.1 million PPP loan forgiveness gain helped reduce reported net loss; it was a nonrecurring item.
- Purchases of marketable securities drove $82.6 million of investing cash outflow. Securities had $183,000 of unrealized losses recorded in other comprehensive loss.
- Anthem-related minimum payments included $3.1 million recorded as deferred revenue and other receivables at year-end; the receivable was collected in January 2022. Revenue is recognized as test results are delivered.
Business outlook, clinical progress, and risks
- Anthem’s February 2021 agreement provides for minimum test purchases and minimum annual payments during the first three years, subject to the agreement’s terms. Sera expects to use the collaboration to support commercialization and pursue broader payer coverage. The filing gives no quantified revenue or earnings guidance.
- PREVENT-PTB results, published in 2021, reported over 70% reductions in hospital and NICU length of stay for preterm infants and a 66% reduction in severe neonatal morbidity or death. The study was not statistically powered to definitively establish reductions in preterm-delivery rates.
- The PRIME randomized study was ongoing, with enrollment of 2,800 patients expected in late 2022 and interim analysis anticipated in the first half of 2023, subject to COVID-19 disruption. COVID-19 had delayed PRIME enrollment and led to early cessation of enrollment in AVERT PRETERM.
- Management expects continuing losses and negative cash flows while it invests in commercialization, clinical studies, and product development. Additional financing may be needed; the company warns that financing may be unavailable or dilutive.
- Key risks include dependence on PreTRM and a limited number of customers, especially Anthem; uncertain payer coverage and reimbursement; adoption and clinical-utility uncertainty; possible FDA regulation of laboratory-developed tests; competition; and reliance on its single CLIA-certified laboratory and suppliers. No material litigation was reported.
- The financial statements received an unqualified audit opinion. Management concluded disclosure controls were effective; the filing included no auditor attestation of internal controls because of the newly public company transition period.
Important facts for investors to verify
- Actual Anthem test volumes, minimum-payment terms, revenue recognition, and renewal or termination conditions.
- Cash burn, marketable-security liquidity, and whether the stated 12-month runway remains adequate as commercialization and trial spending proceed.
- Final clinical outcomes from PRIME and AVERT PRETERM, including whether reported study results are replicated and support payer coverage.
- Progress in obtaining payer coverage and reimbursement beyond Anthem; the CMS price of $750 for the PLA code is not itself proof of broad coverage or realized payment.
- Regulatory developments affecting LDTs, and any changes in laboratory, privacy, or reimbursement requirements.